Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $74.000 million-$76.000 million to $74.000 million-$76.000 ...
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $...
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organiz...
Keybanc analyst Paul Knight initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Sector Weight rating.
Lifecore Biomedical (NASDAQ:LFCR) sees FY2026 sales of $74.000 million-$76.000 million vs $127.802 million analyst estimate.
